

Andrew T Kuykendall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6721726/publications.pdf>

Version: 2024-02-01

46
papers

532
citations

759233

12
h-index

677142

22
g-index

46
all docs

46
docs citations

46
times ranked

725
citing authors

#	ARTICLE	IF	CITATIONS
1	Between a rock and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. <i>Annals of Hematology</i> , 2018, 97, 435-441.	1.8	95
2	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
3	Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. <i>Blood</i> , 2017, 129, 1881-1883.	1.4	54
4	Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. <i>Blood</i> , 2020, 135, 1696-1703.	1.4	54
5	Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1142-1151.	2.0	48
6	A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. <i>Blood Advances</i> , 2022, 6, 1855-1864.	5.2	47
7	Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. <i>American Journal of Hematology</i> , 2019, 94, 87-92.	4.1	18
8	Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data. <i>Annals of Hematology</i> , 2022, 101, 139-146.	1.8	17
9	Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis. <i>Cancers</i> , 2020, 12, 2278.	3.7	15
10	Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. <i>Leukemia Research</i> , 2020, 93, 106367.	0.8	15
11	The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e45-e53.	0.4	13
12	Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	13
13	Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e956-e960.	0.4	9
14	Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 149-149.	1.4	9
15	JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation. <i>Blood Cancer Journal</i> , 2022, 12, 13.	6.2	9
16	Rationale for and Results of a Phase I Study of the TGF- β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial. <i>Blood</i> , 2020, 136, 6-8.	1.4	8
17	Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy. <i>Leukemia Research</i> , 2021, 109, 106640.	0.8	7
18	Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 421-424.e2.	0.4	5

#	ARTICLE	IF	CITATIONS
19	JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 129-141.	1.4	4
20	CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 774-779.	0.4	4
21	Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. <i>Leukemia Research</i> , 2021, 109, 106629.	0.8	3
22	CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (≤ 60 Years Old) Compared to Older Patients (≥ 60 Years Old) with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3894-3894.	1.4	3
23	Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥ 70 Years with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1368-1368.	1.4	3
24	Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2022, 198, 713-720.	2.5	3
25	Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 543-549.	2.3	2
26	Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database. <i>Blood</i> , 2019, 134, 2949-2949.	1.4	2
27	Comparison of different treatment strategies for blast-phase myeloproliferative neoplasms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.4	2
28	Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	2
29	Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis. <i>American Journal of Hematology</i> , 2019, 94, E314-E317.	4.1	1
30	Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e52-e56.	0.4	1
31	Abstract CT236: A Two-Part Phase 2 Study of Itacitinib Immediate Release in Patients with Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy. <i>Cancer Research</i> , 2021, 81, CT236-CT236.	0.9	1
32	SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 3001-3001.	1.4	1
33	Treatment Free Remission in Patients with Chronic Phase CML: A Single Center Experience. <i>Blood</i> , 2021, 138, 3612-3612.	1.4	1
34	A Diagnosis on the LAM: Pulmonary Lymphangiomyomatosis Masquerading as Progressive Mediastinal Lymphadenopathy. <i>Chest</i> , 2014, 146, 354A.	0.8	0
35	Serum Albumin as Prognostic Factor for Overall Survival in Rearranged MYC and BCL2/BCL6 Positive Double Hit Diffuse Large B Cell Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S99.	0.4	0
36	Comparing Eras in Myelofibrosis: Changing Patterns of Treatment Before and After FDA-Approval of Ruxolitinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S91-S92.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Traipsing Through Muddy Waters. Hematology/Oncology Clinics of North America, 2021, 35, 337-352.	2.2	0
38	Stepping out of antiquity: An update on emerging drugs for the treatment of polycythemia vera. Expert Opinion on Emerging Drugs, 2021, 26, 209-218.	2.4	0
39	More Than a Hunch: Need for Close Follow-up and Rebiopsy When Lymphadenopathy Is Not Behaving as Predicted by Infectious Diagnosis: A Case Report. Chest, 2014, 146, 353A.	0.8	0
40	Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acute Myeloid Leukemia. Blood, 2019, 134, 2636-2636.	1.4	0
41	Genetic and Clinical Features of Chronic Myelomonocytic Leukemia with Fibrosis. Blood, 2019, 134, 5442-5442.	1.4	0
42	Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome. Blood, 2019, 134, 4621-4621.	1.4	0
43	RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 2052-2052.	1.4	0
44	A Focus on Phenotype and Genotype: Racial /Ethnic Disparities in Myelodysplastic Syndromes. Blood, 2021, 138, 1985-1985.	1.4	0
45	Upfront Targeted Tyrosine Kinase Inhibitor Therapy Improves Outcome in Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia. Blood, 2021, 138, 3658-3658.	1.4	0
46	Gender Disparities in Myelodysplastic Syndromes: Phenotype, Genotype, and Outcomes. Blood, 2021, 138, 1984-1984.	1.4	0